Correction: Association of aspirin use for primary prevention with cardiovascular events and bleeding events: A systematic review and meta-analysis (JAMA - Journal of the American Medical Association (2019) 321:3 (277-287) DOI: 10.1001/jama.2018.20578);Association of Aspirin Use for Primary Prevention with Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis

JAMA - Journal of the American Medical Association

Volumn 321, Issue 3, 2019, Pages 277-287

  Zheng, Sean L ^a,b,c   Roddick, Alistair J ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO; ANTITHROMBOCYTIC AGENT;

AGE; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; DIABETES MELLITUS; DRUG USE; FOLLOW UP; GENDER; HEART INFARCTION; HUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; CHEMICALLY INDUCED; DIABETIC COMPLICATION; FEMALE; MALE; META ANALYSIS; RISK;

ASPIRIN; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HEMORRHAGE; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; RISK;

EID: 85060215366     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2019.3941     Document Type: Erratum

References (35)

1. Wall HK, Ritchey MD, Gillespie C, Omura JD, Jamal A, George MG. Vital signs: prevalence of key cardiovascular disease risk factors for million hearts 2022-United States, 2011-2016. MMWR Morb Mortal Wkly Rep. 2018; 67 (35): 983-991. doi: 10.15585/mmwr.mm6735a4 30188885
2. Wright JS, Wall HK, Ritchey MD. Million Hearts 2022: small steps are needed for cardiovascular disease prevention. JAMA. 2018; 320 (18): 1857-1858. doi: 10.1001/jama.2018.13326 30193304
3. Ritchey MD, Wall HK, Owens PL, Wright JS. Vital signs: state-level variation in nonfatal and fatal cardiovascular events targeted for prevention by Million Hearts 2022. MMWR Morb Mortal Wkly Rep. 2018; 67 (35): 974-982. doi: 10.15585/mmwr.mm6735a3 30188881
4. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373 (9678): 1849-1860. doi: 10.1016/S0140-6736(09)60503-1 19482214
5. ASCEND Study Collaborative Group, Bowman L, Mafham M. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018; 18 (16): 1529-1539. doi: 10.1056/NEJMoa1804988
6. Gaziano JM, Brotons C, Coppolecchia R, Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018; 392 (10152): 1036-1046. doi: 10.1016/S0140-6736(18)31924-X 30158069
7. Whitlock EP, Burda BU, Williams SB, Guirguis-Blake JM, Evans CV. Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2016; 164 (12): 826-835. doi: 10.7326/M15-2112 27064261
8. Piepoli MF, Hoes AW, Agewall S, 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Eur Heart J. 2016; 37 (29): 2315-2381. doi: 10.1093/eurheartj/ehw106 27222591
9. Guirguis-Blake JM, Evans CV, Senger CA, O'Connor EA, Whitlock EP. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2016; 164 (12): 804-813. doi: 10.7326/M15-2113 27064410
10. Van't Hof JR, Duval S, Walts A, Kopecky SL, Luepker RV, Hirsch AT. Contemporary primary prevention aspirin use by cardiovascular disease risk: impact of US Preventive Services Task Force recommendations, 2007-2015: a serial, cross-sectional study. J Am Heart Assoc. 2017; 6 (10): e006328. doi: 10.1161/JAHA.117.006328 28974502
11. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009; 339: b2535. doi: 10.1136/bmj.b2535 19622551
12. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315 (7109): 629-634. doi: 10.1136/bmj.315.7109.629 9310563
13. Rothwell PM, Fowkes FGR, Belch JFF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011; 377 (9759): 31-41. doi: 10.1016/S0140-6736(10)62110-1 21144578
14. Chubak J, Whitlock EP, Williams SB, Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. Preventive Services Task Force. Ann Intern Med. 2016; 164 (12): 814-825. doi: 10.7326/M15-2117 27064482
15. McNeil JJ, Nelson MR, Woods RL, Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med. 2018; 379 (16): 1519-1528. doi: 10.1056/NEJMoa1803955
16. Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013; 33 (5): 607-617. doi: 10.1177/0272989X12458724 23104435
17. Zheng SL, Roddick AJ, Aghar-Jaffar R, Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA. 2018; 319 (15): 1580-1591. doi: 10.1001/jama.2018.3024 29677303
18. McNeil JJ, Wolfe R, Woods RL, Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018; 379 (3): 1509-1518. doi: 10.1056/NEJMoa1805819
19. Peto R, Gray R, Collins R, Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed). 1988; 296 (6618): 313-316. doi: 10.1136/bmj.296.6618.313 3125882
20. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989; 321 (3): 129-135. doi: 10.1056/NEJM198907203210301 2664509
21. Hansson L, Zanchetti A, Carruthers SG, Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998; 351 (9118): 1755-1762. doi: 10.1016/S0140-6736(98)04311-6 9635947
22. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet. 1998; 351 (9098): 233-241. doi: 10.1016/S0140-6736(97)11475-1 9457092
23. de Gaetano G, Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet. 2001; 357 (9250): 89-95. doi: 10.1016/S0140-6736(00)03539-X 11197445
24. Ridker PM, Cook NR, Lee I-M, A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005; 352 (13): 1293-1304. doi: 10.1056/NEJMoa050613 15753114
25. Belch J, MacCuish A, Campbell I, The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008; 337: a1840. doi: 10.1136/bmj.a1840 18927173
26. Ikeda Y, Shimada K, Teramoto T, Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA. 2014; 312 (23): 2510-2520. doi: 10.1001/jama.2014.15690 25401325
27. Fowkes FGR, Price JF, Stewart MCW, Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010; 303 (9): 841-848. doi: 10.1001/jama.2010.221 20197530
28. Ogawa H, Nakayama M, Morimoto T, Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008; 300 (18): 2134-2141. doi: 10.1001/jama.2008.623 18997198
29. Okada S, Morimoto T, Ogawa H, Effect of aspirin on cancer chemoprevention in Japanese patients with type 2 diabetes: 10-year observational follow-up of a randomized controlled trial. Diabetes Care. 2018; 41 (8): 1757-1764. doi: 10.2337/dc18-0368 29909377
30. Yokoyama K, Ishizuka N, Uemura N, Effects of daily aspirin on cancer incidence and mortality in the elderly Japanese. Res Pract Thromb Haemost. 2018; 2 (2): 274-281. doi: 10.1002/rth2.12097 30046729
31. Cook NR, Lee I-M, Gaziano JM, Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005; 294 (1): 47-55. doi: 10.1001/jama.294.1.47 15998890
32. Rana JS, Tabada GH, Solomon MD, Accuracy of the atherosclerotic cardiovascular risk equation in a large contemporary, multiethnic population. J Am Coll Cardiol. 2016; 67 (18): 2118-2130. doi: 10.1016/j.jacc.2016.02.055 27151343
33. Allan GM, Nouri F, Korownyk C, Kolber MR, Vandermeer B, McCormack J. Agreement among cardiovascular disease risk calculators. Circulation. 2013; 127 (19): 1948-1956. doi: 10.1161/CIRCULATIONAHA.112.000412 23575355
34. Li L, Geraghty OC, Mehta Z, Rothwell PM, Oxford Vascular Study. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet. 2017; 390 (10093): 490-499. doi: 10.1016/S0140-6736(17)30770-5 28622955
35. Zheng SL, Chan FT, Maclean E, Jayakumar S, Nabeebaccus AA. Reporting trends of randomised controlled trials in heart failure with preserved ejection fraction: a systematic review. Open Heart. 2016; 3 (2): e000449. doi: 10.1136/openhrt-2016-000449 27547434